

Neuroblastoma - Pipeline Review, H2 2020

<https://marketpublishers.com/r/N02503ECBC0EN.html>

Date: November 2020

Pages: 1084

Price: US\$ 2,500.00 (Single User License)

ID: N02503ECBC0EN

Abstracts

Neuroblastoma - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma - Pipeline Review, H2 2020, provides an overview of the Neuroblastoma (Oncology) pipeline landscape.

Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuroblastoma - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in

therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 38, 24, 4, 47, 12 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 7, 5, 1, 15 and 1 molecules, respectively.

Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology).

The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Neuroblastoma- Overview

Neuroblastoma- Therapeutics Development

Neuroblastoma- Therapeutics Assessment

Neuroblastoma- Companies Involved in Therapeutics Development

Neuroblastoma- Drug Profiles

Neuroblastoma- Dormant Projects

Neuroblastoma- Discontinued Products

Neuroblastoma- Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Neuroblastoma, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Neuroblastoma - Pipeline by Ability Pharmaceuticals SL, H2 2020
Neuroblastoma - Pipeline by Actuate Therapeutics Inc, H2 2020
Neuroblastoma - Pipeline by ADC Therapeutics SA, H2 2020
Neuroblastoma - Pipeline by Adicet Bio Inc, H2 2020
Neuroblastoma - Pipeline by Advanced Accelerator Applications SA, H2 2020
Neuroblastoma - Pipeline by Alissa Pharma, H2 2020
Neuroblastoma - Pipeline by Allarity Therapeutics A/S, H2 2020
Neuroblastoma - Pipeline by APEIRON Biologics AG, H2 2020
Neuroblastoma - Pipeline by Aptorum Group Ltd, H2 2020
Neuroblastoma - Pipeline by AstraZeneca Plc, H2 2020
Neuroblastoma - Pipeline by AUM Biosciences Pte Ltd, H2 2020
Neuroblastoma - Pipeline by Autolus Therapeutics Plc, H2 2020
Neuroblastoma - Pipeline by Bayer AG, H2 2020
Neuroblastoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2020
Neuroblastoma - Pipeline by Bexion Pharmaceuticals LLC, H2 2020
Neuroblastoma - Pipeline by Bio-Cancer Treatment International Ltd, H2 2020
Neuroblastoma - Pipeline by BioEclipse Therapeutics Inc, H2 2020
Neuroblastoma - Pipeline by Biogenera SpA, H2 2020
Neuroblastoma - Pipeline by BioLineRx Ltd, H2 2020
Neuroblastoma - Pipeline by BioVec Pharma Inc, H2 2020
Neuroblastoma - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
Neuroblastoma - Pipeline by Bristol-Myers Squibb Co, H2 2020
Neuroblastoma - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2020
Neuroblastoma - Pipeline by Cebiotex SL, H2 2020
Neuroblastoma - Pipeline by Celldex Therapeutics Inc, H2 2020
Neuroblastoma - Pipeline by Collectar Biosciences Inc, H2 2020

Neuroblastoma - Pipeline by Chiome Bioscience Inc, H2 2020
Neuroblastoma - Pipeline by Clarity Pharmaceuticals Pty Ltd, H2 2020
Neuroblastoma - Pipeline by Cleveland BioLabs Inc, H2 2020
Neuroblastoma - Pipeline by CorMedix Inc, H2 2020
Neuroblastoma - Pipeline by Curis Inc, H2 2020
Neuroblastoma - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2020
Neuroblastoma - Pipeline by DEKK-TEC Inc, H2 2020
Neuroblastoma - Pipeline by Eli Lilly and Co, H2 2020
Neuroblastoma - Pipeline by Epigene Therapeutics Inc, H2 2020
Neuroblastoma - Pipeline by Epizyme Inc, H2 2020
Neuroblastoma - Pipeline by Errant Gene Therapeutics LLC, H2 2020
Neuroblastoma - Pipeline by EUSA Pharma (UK) Ltd, H2 2020
Neuroblastoma - Pipeline by Expression Therapeutics LLC, H2 2020
Neuroblastoma - Dormant Projects, H2 2020
Neuroblastoma - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Neuroblastoma, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

I would like to order

Product name: Neuroblastoma - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/N02503ECBC0EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N02503ECBC0EN.html>